 |
|
Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Angioid Streaks
Michele Rinaldi, MD;
Roberto dell’Omo, MD;
Mario R. Romano, MD;
Flavia Chiosi, MD;
Ugo Cipollone, MD;
Ciro Costagliola, MD
Arch Ophthalmol. 2007;125(10):1422-1423.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Angioid streaks (AS) are irregular ruptures of the Bruch membrane that typically radiate from the optic disc. Through these cracks, new blood vessels may proliferate, generating choroidal neovascularization (CNV), which represents the main cause of visual loss in these patients.1 Laser photocoagulation has been widely used both to stop CNV and to stabilize visual acuity (VA) in patients with AS. The high rate of recurrences and functional problems related to the expansion of CNV or laser-induced scar toward the fovea have encouraged the evaluation of different treatment options. Photodynamic therapy (PDT) with verteporfin has been used to limit or delay visual damage caused by this aggressive disease,2 but its efficacy on macular function seems to be limited to a short period.
Vascular endothelial growth factor (VEGF) has been implicated in several . . . [Full Text of this Article] Report of Cases
Comment
AUTHOR INFORMATION
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Management of choroidal vascularisation
Lommatzsch
Br. J. Ophthalmol. 2008;92:445-446.
FULL TEXT
|
